Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment

Cancer Treatment Reviews, 05/24/2012

This analysis demonstrated that in a high proportion of patients Len/Dex treatment can reverse multiple myeloma (MM)–related Renal impairment (RI) and restore normal function. Lenalidomide has a predominantly renal route of excretion and in patients with RI the plasma concentration and half–life of the drug are significantly increased. As a consequence, lower starting doses are required in patients with RI to avoid over–exposure and an increased risk of adverse events, while maintaining good therapeutic index.

Print Article Summary Cat 2 CME Report